Paracetamol maker Granules India target of cyber-attack

Granules India has warned of a potential loss of revenue due to a cyber security attack that affected the pharmaceuticals company recently.

Due to significant changes in its IT systems, the IT security incident caused a major disruption in its business operations, the Paracetamol maker said in an exchange filing.  

On 25 May, Granules India reported the information security incident, adding that impacted IT assets affected have been isolated.

The company added that a ransomware group had claimed responsibility for the incident.

The company said it had managed to restore production to near-normal levels at present, however it flagged backlogs and delays in the clearance of materials for quality system approvals for dispatching the products.

Granules India Limited is an Indian pharmaceutical manufacturing company based in Hyderabad, India. Granules manufactures several off-patent drugs, including Paracetamol, Ibuprofen, Metformin and Guaifenesin, on a large scale for customers in the regulated and rest of the world markets.

Granules has seven manufacturing facilities; six are in India while the seventh is through a joint-venture with Hubei Biocase in Wuhan, China. The company also has two research centres, at Hyderabad and Pune.

The Gagillapur facility is located near Hyderabad and has a Finished Dosage block, a PFI block and a research & development facility